A shift in the balance between two lipids – cholesterol and sphingomyelin – makes hybrid epithelial-mesenchymal cancer cells less responsive to certain chemotherapy drugs.
A replication stress–ELF3 axis enables luminal progenitor transformation in BRCA1-deficient breast cancer by reducing genomic instability and promoting progenitor identity.
Kyle Spinler, Michael Hamilton ... Tannishtha Reya
A naturally occurring Musashi2 genetic translocation reported to occur in blast crisis chronic myelogenous leukemia patients can act as an oncogene and drive myeloid leukemia.
Megan E Patton, Sherwin Kelekar ... Sayeepriyadarshini Anakk
Transcriptomic and metabolite analysis reveal sex differences in circulation and excretion of bile acids in a mouse- model of hepatocellular carcinoma (HCC), and the identified female-specific gene profile correlates with better HCC survival.
Maintaining CDK4/6 inhibition constrains drug‑resistant breast tumors by delaying cell‑cycle entry, and adding CDK2 inhibition further deepens control to guide post‑progression therapy.
Using drugs that inhibit enzymes called CDK4/6 and CDK2 extends the G1 phase of the cell cycle and helps to slow the growth of drug-resistant breast cancer.
Genes steadily associated with prognosis define conserved mitotic and immune programs that robustly predict cancer patient survival and therapeutic resistance across tumor types.
Francine C Cadoná, Thais F Bartelli ... Emmanuel Dias-Neto
Elevated gfDNA supports gastric cancer diagnosis and may guide management when combined with tissue biopsies, and in established cancer, higher gfDNA may predict better outcomes, potentially indicating immune-cell infiltration.
Distinct transcriptional subtypes in PPGLs link molecular programs with immune context, providing biomarkers for recurrence risk and therapeutic targeting.
An integrative analysis of scRNA-seq and spatial transcriptomics provides complementary views into the biology of pre-clinical colorectal cancer models in mice with possible applications to the human system.